"Geroprotector" is a scientific term, not a regulatory or marketing one — and that gap is exactly where a lot of longevity-supplement confusion comes from.
A geroprotector is any compound — drug, supplement, or naturally occurring molecule — being studied for its ability to slow, prevent, or partially reverse the biological processes of aging, as opposed to treating a single age-related disease in isolation.
The term comes from geroscience research, not from the FDA or any other regulatory body. There is no such thing as an FDA-approved geroprotector, because the FDA does not currently recognize "aging" itself as a treatable indication — every drug on Geroevidence's index that carries an approved indication (metformin, GLP-1 agonists, SGLT2 inhibitors) is approved for a specific disease, and its geroprotective use is off-label by definition. This is a structural feature of how drug regulation works, not a comment on the underlying science.
Being "studied as a geroprotector" is a description of research intent, not a verdict on results. Some compounds studied this way have hard human outcome data behind them (GLP-1 agonists, with a cardiovascular mortality hazard ratio from the SELECT trial); others have only mouse lifespan data from a program like the NIA's Interventions Testing Program (acarbose, 17α-estradiol); and others have only mechanistic or surrogate-endpoint human data (rapamycin, GlyNAC, most NAD+ precursors). Calling all of these "geroprotectors" without distinguishing the evidence behind each is where most of the hype in this space originates.
Geroevidence's four-tier evidence ladder — Strong, Moderate, Emerging, Insufficient — exists specifically to answer the question a bare "geroprotector" label doesn't: how much, and what kind, of evidence backs a given compound right now. Strong means Phase III RCT evidence with a hard outcome; Moderate means multiple concordant RCTs or one large RCT plus meta-analytic support; Emerging means a single RCT or small pooled-trial signal; Insufficient means pre-clinical or very early human data only. A compound can be a legitimate geroprotector candidate — mechanistically coherent, actively researched — while still sitting at Emerging or Insufficient, because those tiers describe trial maturity, not biological plausibility.
GLP-1 agonists and SGLT2 inhibitors sit at the strong end — approved drugs with hard cardiovascular outcome trials that happen to show geroprotective-relevant effects. Metformin and acarbose sit in the middle, with either meta-analytic mortality data or mouse lifespan data behind an approved-drug safety record. Rapamycin, GlyNAC, NMN, NR, taurine, spermidine, and Urolithin A sit at the earlier end — real mechanistic rationale and small human trials, but no hard outcome data yet. All of these are legitimately "studied as geroprotectors." Only some have accumulated enough evidence to justify strong claims.
"Geroprotector" tells you what a compound is being researched for. It does not tell you how strong that research is. When evaluating any claim that uses the word, the useful next question is always the same one Geroevidence's tiers are built to answer: what specific trial, in what population, showed what specific outcome?
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.